Herpes Simplex Virus-2 is a sexually transmitted viral infection, which often produces painful sores, usually in the genital area. Once infected, an individual may carry the virus and be subject to recurrent bouts of infection. Some estimate that as many as 20 percent of the adult population in the United States has been exposed to the virus.
A new gene therapy approach that attracts and "trains" immune system cells to destroy deadly brain cancer cells also provides long-term immunity, produces no significant adverse effects and -- in the process of destroying the tumor -- promotes the return of normal brain function and behavioral skills, according to a study conducted by researchers at Cedars-Sinai Medical Center's Board of Governors Gene Therapeutics Research Institute.
Researchers in a multi-institutional study led by Cincinnati Children's Hospital Medical Center slowed the growth of two particularly stubborn solid tumor cancers - neuroblastoma and peripheral nerve sheath tumors - without harming healthy tissues by inserting instructions to inhibit tissue growth into an engineered virus, according to study results published in the February 15 Cancer Research.
Viral meningitis is common, but many cases go unreported, say researchers in this week's BMJ.
University of Pennsylvania researchers have uncovered an important step in how herpes simplex virus, HSV-1, uses cooperating proteins found on its outer coat to gain entry into healthy cells and infect them.
Cancer-killing viruses are a promising therapy for incurable brain tumors, but their effectiveness has been limited in part because immune cells rapidly move in and eliminate them.
A recent study of men co-infected with herpes simplex virus type 2 (HSV-2) and HIV revealed that drugs used to suppress HSV decrease the levels of HIV in the blood and rectal secretions, which may make patients less likely to transmit the virus.
What are the cancer drugs of tomorrow and how will they be developed? At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers will present some answers to these and other pressing questions regarding emerging cancer therapeutics.
A team of University of Kentucky researchers has identified the roles that herpes simplex virus type 1 (HSV-1) proteins play during the invasion of cells and the formation of skin lesions known as cold sores and fever blisters.
Long-term anti-herpes treatment of women infected with both HIV and HSV2, the virus that causes genital herpes, may reduce the proportion of women with detectable HIV virus in their genital secretions according to the results of a trial in Tanzania presented the International AIDS Society Conference in Sydney.
A genetically engineered herpes simplex virus, primarily known for causing cold sores, may help keep arteries "free-flowing" in the weeks following angioplasty or stent placement for patients, according to research published early in the online edition of PNAS (Proceedings of the National Academy of Sciences of the United States of America).
Scientists have developed a virus specifically designed to target cancer tissue while not affecting normal healthy tissue.
A virus that has been specifically designed by scientists to be safe to normal tissue but deadly to cancer is showing early promise in a preliminary study, researchers said at the ESMO Conference Lugano (ECLU), Switzerland.
Rats with erectile dysfunction, or ED, that were injected with a gene therapy vector containing either of two nerve growth factors were able to regain normal function after four weeks, according to a study conducted by University of Pittsburgh School of Medicine researchers.
Researchers from the University of Pittsburgh School of Medicine report that they have successfully used gene therapy to block the pain response in an animal model of neuropathic pain, a type of chronic pain in people for which there are few effective treatments.
By adulthood, most people have suffered at least one bout of painful cold sores brought on by the Herpes simplex virus 1, also known as HSV-1.
They say this strategy could offer a novel way of treating many cancers associated with Epstein-Barr, including at least four different types of lymphoma and nasopharyngeal and gastric cancers.
Treatment of genital herpes could slow the progression of HIV in people living with both viruses, according to a study published in the Feb. 22 issue of the New England Journal of Medicine.
Experts call for HSV control measures, including vaccine, to rank high on international HIV prevention and research agenda as exciting trial findings are published.
A researcher at Montana State University has called for an innovative, new approach in developing a vaccine against genital herpes.
For the first time, researchers have identified a peptide that can spur cargo transport in nerve cells, a discovery that could help scientists better understand nerve cell function and test possible therapies for neurodegenerative diseases.